Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients.
Interleukin 6 and C-reactive protein (CRP) were determined prior to IL-2 therapy in sera from metastatic melanoma patients. Patients with elevated serum IL-6 (> 20 pg ml-1) and/or CRP (> 10 mg l-1) levels were associated with resistance to IL-2 therapy. A correlation between high serum IL-6 levels and a shorter median survival was also observed.
Tartour
E
E
Laboratoire d'Immunologie Clinique, Institut Curie, Paris, France.
Dorval
T
T
Mosseri
V
V
Deneux
L
L
Mathiot
C
C
Brailly
H
H
Montero
F
F
Joyeux
I
I
Pouillart
P
P
Fridman
W H
WH
D000328:Adult; D000368:Aged; D002097:C-Reactive Protein / Q000378:metabolism*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D015850:Interleukin-6 / Q000097:blood*; D008297:Male; D008545:Melanoma / Q000097:blood* / Q000401:mortality / Q000628:therapy*; D008875:Middle Aged; D011379:Prognosis
D007376:Interleukin-2; D015850:Interleukin-6; D002097:C-Reactive Protein